drugset / Trial / NCT02597829

Does Clinical Response Correlate With Serum Certolizumab Levels?

NCT02597829

NaSingle-groupOpen-labelTreatment

Summary

A prospective open label trial of adult patients with active Crohn's disease to determine if plasma concentrations of certolizumab pegol correlate to mucosal healing.

Timeline

Start
2015-11
Primary completion
2018-05
Completion
2018-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Certolizumab Pegol Protein / enzyme biologic Subcutaneous

Indications